Jeffrey Gelfand, MD

Neurologist

Dr. Jeffrey Gelfand is a neurologist who specializes in caring for patients with a wide range of autoimmune, inflammatory and neurodegenerative neurological disorders. This includes multiple sclerosis (MS), neurosarcoidosis, encephalitis, meningitis, transverse myelitis, optic neuritis, neuromyelitis optica, central nervous system vasculitis, autoimmune dementias and encephalopathies, autoimmune cerebellar ataxia, and paraneoplastic neurological syndromes. He also treats neurological problems in people with rheumatological and other systemic inflammatory or medical illnesses.

Gelfand received his medical degree from Harvard Medical School. He then completed an internship in internal medicine, a residency in neurology and fellowship training in multiple sclerosis and neuroimmunology, all at UCSF. Gelfand went on to earn a master's degree in advanced study in clinical research at UCSF.

As director of the Multiple Sclerosis Center's Clinical Fellowship Training Program at UCSF, Gelfand trains specialists in multiple sclerosis and neuroimmunology after their neurology residency. Gelfand received the Robert B. Layzer teaching award in 2014 and an Excellence in Teaching Award from the UCSF Haile T. Debas Academy of Medical Educators in 2015.

Gelfand was elected as a fellow of the American Academy of Neurology and serves as a member of the organization's clinical research subcommittee. In 2016, Gelfand chaired the American Neurological Association's autoimmune neurology special interest group.

Gelfand is an assistant professor of clinical neurology at UCSF.

Clinics

Memory and Aging Center
1500 Owens St., Suite 320
San Francisco, CA 94158
Phone: (415) 353-2057
Fax: (415) 353-8292

Hours: Monday to Friday
8 a.m. – 5 p.m.

Multiple Sclerosis Center
1500 Owens St., Suite 320
San Francisco, CA 94158
Phone: (415) 353-2069
Fax: (415) 353-2633

Hours: Monday to Friday
8 a.m. – 5 p.m.

Board Certification

Neurology, American Board of Psychiatry and Neurology

Academic Title

Assistant Professor

More about Jeffrey Gelfand

Education

Harvard School of Medicine 2006
UCSF, Masters in Advanced Study in Clinical Research 2013

Residencies

UCSF Medical Center, Neurology 2010

Fellowships

UCSF Medical Center, Multiple Sclerosis and Neuroimmunology 2011

Selected Research and Publications

  1. Benn BS, Lehman Z, Kidd SA, Miaskowski C, Sunwoo BY, Ho M, Sun S, Ramstein J, Gelfand JM, Koth LL. Sleep disturbance and symptom burden in sarcoidosis. Respir Med. 2018 Mar 24.
  2. Das G, Damotte V, Gelfand JM, Bevan C, Cree BAC, Do L, Green AJ, Hauser SL, Bove R. Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD. Neurol Neuroimmunol Neuroinflamm. 2018 May; 5(3):e453.
  3. Hall DA, Ramos AR, Gelfand JM, Videnovic A, Benatar M, Cahill C, Kluger BM, Goldman M. The state of clinical research in neurology. Neurology. 2018 Apr 10; 90(15):e1347-e1354.
  4. Thompson J, Bi M, Murchison AG, Makuch M, Bien CG, Chu K, Farooque P, Gelfand JM, Geschwind MD, Hirsch LJ, Somerville E, Lang B, Vincent A, Leite MI, Waters P, Irani SR. The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain. 2018 Feb 01; 141(2):348-356.
  5. Damotte V, Lize A, Tremblay M, Agrawal A, Khankhanian P, Santaniello A, Gomez R, Lincoln R, Tang W, Chen T, Lee N, Villoslada P, Hollenbach JA, Bevan CD, Graves J, Bove R, Goodin DS, Green AJ, Baranzini SE, Cree BA, Henry RG, Hauser SL, Gelfand JM, Gourraud PA. Harnessing electronic medical records to advance research on multiple sclerosis. Mult Scler. 2018 Jan 01; 1352458517747407.
  6. Baud MO, Vitt JR, Robbins NM, Wabl R, Wilson MR, Chow FC, Gelfand JM, Josephson SA, Miller S. Pleocytosis is not fully responsible for low CSF glucose in meningitis. Neurol Neuroimmunol Neuroinflamm. 2018 Jan; 5(1):e425.
  7. Gelfand JM. Demystifying Neurosarcoidosis and Informing Prognosis. JAMA Neurol. 2017 Nov 01; 74(11):1296-1298.
  8. Gelfand JM, Bradshaw MJ, Stern BJ, Clifford DB, Wang Y, Cho TA, Koth LL, Hauser SL, Dierkhising J, Vu N, Sriram S, Moses H, Bagnato F, Kaufmann JA, Ammah DJ, Yohannes TH, Hamblin MJ, Venna N, Green AJ, Pawate S. Infliximab for the treatment of CNS sarcoidosis: A multi-institutional series. Neurology. 2017 Nov 14; 89(20):2092-2100.
  9. Green AJ, Gelfand JM, Cree BA, Bevan C, Boscardin WJ, Mei F, Inman J, Arnow S, Devereux M, Abounasr A, Nobuta H, Zhu A, Friessen M, Gerona R, von Bdingen HC, Henry RG, Hauser SL, Chan JR. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet. 2017 Dec 02; 390(10111):2481-2489.
  10. Gelfand JM, Cree BAC, Hauser SL. Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis. Neurotherapeutics. 2017 Oct; 14(4):835-841.
  11. Tremblay MA, Villanueva-Meyer JE, Cha S, Tihan T, Gelfand JM. Clinical and imaging correlation in patients with pathologically confirmed tumefactive demyelinating lesions. J Neurol Sci. 2017 Oct 15; 381:83-87.
  12. Benn BS, Lehman Z, Kidd SA, Ho M, Sun S, Ramstein J, Arger NK, Nguyen CP, Su R, Gomez A, Gelfand JM, Koth LL. Clinical and Biological Insights from the University of California San Francisco Prospective and Longitudinal Cohort. Lung. 2017 Oct; 195(5):553-561.
  13. Ward ME, Chen R, Huang HY, Ludwig C, Telpoukhovskaia M, Taubes A, Boudin H, Minami SS, Reichert M, Albrecht P, Gelfand JM, Cruz-Herranz A, Cordano C, Alavi MV, Leslie S, Seeley WW, Miller BL, Bigio E, Mesulam MM, Bogyo MS, Mackenzie IR, Staropoli JF, Cotman SL, Huang EJ, Gan L, Green AJ. Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis. Sci Transl Med. 2017 Apr 12; 9(385).
  14. Karageorgiou, E., Naasan, G., Pleasure, S.J., Alexandrescu, S., Gelfand, J.M., Tammewar, G., Miller, B.L., Rabinovici, G.D. and Grinberg, L.T., . Focal cerebral -amyloid angiopathy A distinct clinicopathologic presentation. Neurology: Clinical Practice. 2017.
  15. Gelfand JM. Risk of Multiple Sclerosis After a Clinically Isolated Syndrome: From Magnetic Resonance Imaging to Oligoclonal Bands to Activated T Cells. JAMA Neurol. 2017 Mar 01; 74(3):262-263.
  16. Casaletto KB, Ward ME, Baker NS, Bettcher BM, Gelfand JM, Li Y, Chen R, Dutt S, Miller B, Kramer JH, Green AJ. Retinal thinning is uniquely associated with medial temporal lobe atrophy in neurologically normal older adults. Neurobiol Aging. 2017 Mar; 51:141-147.
  17. Block VJ, Lize A, Crabtree-Hartman E, Bevan CJ, Graves JS, Bove R, Green AJ, Nourbakhsh B, Tremblay M, Gourraud PA, Ng MY, Pletcher MJ, Olgin JE, Marcus GM, Allen DD, Cree BA, Gelfand JM. Continuous daily assessment of multiple sclerosis disability using remote step count monitoring. J Neurol. 2017 Feb; 264(2):316-326.
  18. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016 Oct; 80(4):499-510.
  19. Miloslavsky EM, Naden RP, Bijlsma JW, Brogan PA, Brown ES, Brunetta P, Buttgereit F, Choi HK, DiCaire JF, Gelfand JM, Heaney LG, Lightstone L, Lu N, Murrell DF, Petri M, Rosenbaum JT, Saag KS, Urowitz MB, Winthrop KL, Stone JH. Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. Ann Rheum Dis. 2017 Mar; 76(3):543-546.
  20. Balk LJ, Cruz-Herranz A, Albrecht P, Arnow S, Gelfand JM, Tewarie P, Killestein J, Uitdehaag BM, Petzold A, Green AJ. Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study. J Neurol. 2016 Jul; 263(7):1323-31.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.